CLOFARABINE

Clofarabine is a purine nucleoside antimetabolite used in the treatment of acute lymphoblastic leukemia (ALL) and other hematologic malignancies. It inhibits DNA synthesis, leading to apoptosis of cancer cells.

Indications

-Acute Lymphoblastic Leukemia (ALL) in pediatric patients who have relapsed or are refractory to other treatments. -Other hematologic malignancies as determined by a healthcare professional.

Dosage

-Pediatric Patients (1-21 years old): 52 mg/m² administered intravenously over 2 hours daily for 5 consecutive days every 2 to 6 weeks. -Adjustments: Dose modifications may be required based on toxicity and patient response.

Contra-Indications

-Hypersensitivity to Clofarabine or any of its components. -Severe hepatic or renal impairment. -Pregnancy and breastfeeding.

Special Precautions

-Monitor renal and hepatic function before and during treatment. -Increased risk of infections due to myelosuppression. -Risk of capillary leak syndrome and systemic inflammatory response syndrome. -Hydration and prophylactic antiemetics recommended to manage side effects.

Side Effects

-Common: Nausea, vomiting, diarrhea, fever, fatigue, rash, and myelosuppression. -Serious: Hepatotoxicity, nephrotoxicity, tumor lysis syndrome, capillary leak syndrome, and hypotension.

Drug Interactions

-Increased toxicity when combined with other myelosuppressive agents. -Potential interactions with hepatotoxic or nephrotoxic drugs. -Avoid live vaccines during treatment.